Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effect of therapeutic horseback riding on balance and gait of people with multiple sclerosis.
10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
Glatiramer Acetate Protects Against Inflammatory Synaptopathy in Experimental Autoimmune Encephalomyelitis.
Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.
Arginase-1 is expressed exclusively by infiltrating myeloid cells in CNS injury and disease.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.
Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa.
Neurotrophic and Neuroprotective effects of muscle contraction.
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.
Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis.
Multiple Sclerosis: An Update.
Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
Factors in Patient Empowerment: A Survey of an Online Patient Research Network.
Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.
Neurovascular coupling in patients with relapsing-remitting multiple sclerosis.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Plasma ubiquitin?proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
Developing a Valuation Function for the Preference-Based Multiple Sclerosis Index: Comparison of Standard Gamble and Rating Scale.
Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity.
10 years of interferon beta-1b (Beta feron therapy.
Interferon-beta1b for the treatment of multiple sclerosis.
Genetic analysis of aquaporin-4 in neuromyelitis optica.

Pages